Impact of maternal marijuana use on epigenetic regulation of offspring neurodevelopment
Project Number5DP1DA056493-03
Contact PI/Project LeaderLO, JAMIE
Awardee OrganizationOREGON HEALTH & SCIENCE UNIVERSITY
Description
Abstract Text
PROJECT SUMMARY
Marijuana is now the most commonly used illicit drug in pregnancy. The main psychoactive compound of
marijuana, delta-9-tetrahydrocannabinol (THC), can access and bind to cannabinoid receptors in the placenta
and fetal brain. Preliminary data suggest that prenatal cannabinoid exposure results in epigenetic changes in
the placenta and brains of exposed offspring. This is concerning because the placenta plays a key role in fetal
growth and development by mediating fetal nutrition, oxygenation, inflammatory signaling, and transmission of
maternal environmental exposures. Compromises to placental function can adversely affect brain development.
Epigenetic responses to maternal marijuana use likely result in molecular alterations in gene regulation of
offspring developmental trajectories towards neurodevelopmental morbidity, including addiction, autism
spectrum disorder, attention deficit hyperactivity disorder, and cognitive disabilities. Specifically, prenatal THC
exposure is known to alter reward processing, by histone modification of ventral striatal dopaminergic signaling,
affecting addiction vulnerability. However, a mechanistic link between maternal THC use and its impact on
offspring epigenetic regulation of neurodevelopment is impeded by the lack of in vivo longitudinal assessment
secondary to the limitations of current imaging capabilities and feasibility of tissue sampling. We propose to
address this problem by defining a trajectory of perturbed epigenetic regulation following in utero THC exposure
across fetal and early childhood brain and behavioral development. To this end, we will employ three innovative
and complementary approaches using our novel, non-human primate model of chronic maternal THC use: 1)
first-in-kind, longitudinal in vivo imaging of placental and fetal epigenetic regulation and development, 2)
extensive postnatal assessment of infant cognition and behavior, and 3) sophisticated tissue studies confirming
the role of epigenetic modifications in the imaging and behavioral studies. In summary, our study will interrogate
the previously inaccessible mechanistic links underlying the impact of maternal marijuana use on fetal origins of
health, disease and addiction risk. The successful completion of our study will result in 1) new insights into the
impact of maternal THC use on the developing fetal and infant brain, 2) the impact of THC-induced epigenetic
alterations on trajectories of offspring neurodevelopment and behavioral regulation 3) the creation of a
comprehensive, longitudinal in vivo map of offspring epigenetic regulation of neurodevelopment from fetal life to
early childhood, and 4) characterization of ex vivo epigenetic and transcriptomic assessments that can be used
as a reference for other drugs of abuse and environmental exposures. This study has the potential for immediate
translational impact, given the high prevalence of prenatal and postnatal marijuana use and limited data on
longer-term offspring outcomes and contribution to drug addiction. The study’s ultimate goal is to provide
appropriate guidance for women using marijuana who are trying to conceive, are pregnant, or are lactating, and
for clinicians to consider early intervention and screening of offspring exposed prenatally to marijuana.
Public Health Relevance Statement
PROJECT NARRATIVE
The objective of this project is to understand the impact of maternal marijuana use on epigenetic regulation
and neurodevelopment in offspring spanning fetal life to early childhood, predisposing to addiction vulnerability
later in life, in a non-human primate (NHP) model. The successful completion of our study will result in 1) new
insights into the impact of maternal THC use on the developing fetal and infant brain, 2) the impact of THC-
induced epigenetic alterations on trajectories of offspring neurodevelopment and behavioral regulation 3) the
creation of a comprehensive, longitudinal in vivo map of offspring epigenetic regulation of neurodevelopment
from fetal life to early childhood, and 4) characterization of ex vivo epigenetic and transcriptomic assessments
that can be used as a reference for other drugs of abuse and environmental exposures.
No Sub Projects information available for 5DP1DA056493-03
Publications
Publications are associated with projects, but cannot be identified with any particular year of the project or fiscal year of funding. This is due to the continuous and cumulative nature of knowledge generation across the life of a project and the sometimes long and variable publishing timeline. Similarly, for multi-component projects, publications are associated with the parent core project and not with individual sub-projects.
No Publications available for 5DP1DA056493-03
Patents
No Patents information available for 5DP1DA056493-03
Outcomes
The Project Outcomes shown here are displayed verbatim as submitted by the Principal Investigator (PI) for this award. Any opinions, findings, and conclusions or recommendations expressed are those of the PI and do not necessarily reflect the views of the National Institutes of Health. NIH has not endorsed the content below.
No Outcomes available for 5DP1DA056493-03
Clinical Studies
No Clinical Studies information available for 5DP1DA056493-03
News and More
Related News Releases
No news release information available for 5DP1DA056493-03
History
No Historical information available for 5DP1DA056493-03
Similar Projects
No Similar Projects information available for 5DP1DA056493-03